Vyne <a href="https://laohu8.com/S/LENZ">Therapeutics</a> reports third quarter results and updates on pipeline progress
Vyne Therapeutics Inc. reported a net loss of $7.3 million, or $0.17 per share, for the third quarter ended September 30, 2025, compared to a net loss of $12.2 million, or $0.29 per share, for the same period in 2024. Research and development expenses decreased by 48.7% to $5.3 million, primarily due to lower expenses for repibresib and VYN202 following the termination of a Phase 2b trial in nonsegmental vitiligo and reduced clinical expenses, partially offset by a $1.0 million milestone payment for VYN202. General and administrative expenses were $2.7 million, down 8.7% from the prior year. The company reported a cash runway into the first half of 2027, citing previously announced cost reductions. Vyne is continuing a 12-week non-clinical toxicology study for VYN202 and is progressing with a strategic review to evaluate options for maximizing shareholder value, including pipeline opportunities and broader strategic alternatives.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vyne Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001566044-25-000007), on November 06, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.